Prostaglandin F2-alpha Eye Drops (Bimatoprost) in Thyroid Eye Disease: a Randomised Controlled Double Blind Crossover Trial
Phase of Trial: Phase IV
Latest Information Update: 12 Aug 2019
Price : $35 *
At a glance
- Drugs Bimatoprost (Primary)
- Indications Graves ophthalmopathy
- Focus Therapeutic Use
- Acronyms BIMA
- 29 Feb 2016 Status changed from active, no longer recruiting to completed, according to ISRCTN: Current Controlled Trials record.
- 10 Apr 2015 Status changed from recruiting to active, no longer recruiting as reported by United Kingdom Clinical Research Network.
- 04 Mar 2015 Accrual to date is 100% according to United Kingdom Clinical Research Network record